Viatris Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 11/29/2023
Viatris Inc Stock Forecast and Price Target
The average price target for Viatris Inc's stock of $11.50 recently provided by eight leading analysts would represent a 25.82% upside from its last closing price if reached. This potential increase is based on a high estimate of $14.00 and a low estimate of $9.00. You may be interested in rivals even if you aren't interested in Viatris Inc stock.
25.82% Upside
Viatris Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Viatris Inc's Price has fallen from $18.87 to $14.30 – a 24.21% decrease. For next year, analysts predict Fair Value of $14.69, which would mean an increase of 2.69%. Over the next eight years, experts predict that Viatris Inc's Fair Value will grow at a rate of 23.88%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly & Co | Outperform |
16
|
$591.60 | Buy/Sell | $594.01 | 9.87% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$151.63 | Buy/Sell | $176.14 | 13.43% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$100.18 | Buy/Sell | $123.75 | 24.78% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$29.69 | Buy/Sell | $40.55 | 26.31% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$48.92 | Buy/Sell | $64.26 | 25.72% |
Viatris Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Viatris Inc's Revenue has grown by 41.41%, rising from $11.50B to $16.26B. For next year, analysts predict Revenue of $16.63B, which would mean an increase of 2.27%. Over the next eight years, experts predict that Viatris Inc's Revenue will grow at a rate of 5.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
15
|
$347.04 | Buy/Sell | $395.90 | 12.38% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$801.14 | Buy/Sell | $796.73 | 14.09% |
| ZTS Stock Forecast | Zoetis Inc | Outperform |
18
|
$176.97 | Buy/Sell | $217.57 | 18.66% |
.jpg)
Viatris Inc Dividend per Share Forecast for 2023 - 2025 - 2030
In the last year, Viatris Inc's Dividend per Share has grown by 6.67%, rising from $0.45 to $0.48. For next year, analysts predict Dividend per Share of $0.51, which would mean an increase of 6.25%. In 2030, professionals predict that Viatris Inc's Dividend per Share will decrease by 17.52%, to $0.40.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$161.36 | Buy/Sell | $245.24 | 42.54% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$36.34 | Buy/Sell | $45.50 | 22.45% |
| UTHR Stock Forecast | United Therapeutics Corp | Outperform |
12
|
$230.39 | Buy/Sell | $278.82 | 30.21% |
Viatris Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
Viatris Inc's Free Cash Flow has grown In the last three years, rising from $1.59B to $2.71B – a growth of 70.36%. In the next year, analysts believe that Free Cash Flow will reach $3.62B – an increase of 33.53%. For the next eight years, experts predict that Viatris Inc's Free Cash Flow will grow at a rate of 52.20%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals Inc | Outperform |
9
|
$48.34 | Buy/Sell | $51.20 | 24.12% |
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$39.46 | Buy/Sell | $49.29 | 21.64% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$122.71 | Buy/Sell | $145.00 | 22.24% |
Viatris Inc Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Viatris Inc's Net Income has grown, rising from $16.80M to $2.08B – a growth of 12272.62%. In the next year, analysts believe that Net Income will reach $4.15B – an increase of 99.70%. For the next eight years, the forecast is for Net Income to grow by 144.30%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$190.94 | Buy/Sell | $170.08 | 73.09% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$16.60 | Buy/Sell | $37.00 | 34.04% |
| CYTK Stock Forecast | Cytokinetics Inc | Outperform |
10
|
$31.22 | Buy/Sell | $61.75 | 92.18% |
Viatris Inc EBITDA Forecast for 2023 - 2025 - 2030
Viatris Inc's EBITDA has seen impressive growth In the last three years, rising from $3.26B to $5.70B – a growth of 74.84%. In the next year, analysts believe that EBITDA will reach $5.99B – an increase of 5.05%. For the next eight years, the forecast is for EBITDA to grow by 26.10%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$54.41 | Buy/Sell | $69.00 | 21.30% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$25.45 | Buy/Sell | $0.00 | 41.45% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£12.38 | Buy/Sell | £3.79 | 134.25% |
Viatris Inc EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Viatris Inc's EBIT has grown by 100.20%, rising from $1.42B to $2.85B. For the next year, analysts predict that EBIT will reach $5.60B – an increase of 96.65%. Over the next eight years, experts believe that Viatris Inc's EBIT will grow at a rate of 122.20%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$12.63 | Buy/Sell | $26.83 | 90.02% |
| CPRX Stock Forecast | Catalyst Pharmaceuticals | Outperform |
16
|
$14.21 | Buy/Sell | $23.30 | 75.93% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Outperform |
14
|
$9.68 | Buy/Sell | $17.40 | 106.61% |
Viatris Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Viatris Inc's EPS has fallen from $4.42 to $3.35 – a 24.21% decrease. For next year, analysts predict EPS of $3.44, which would mean an increase of 2.69%. Over the next eight years, experts predict that Viatris Inc's EPS will grow at a rate of 23.88%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$26.97 | Buy/Sell | $41.00 | 53.87% |
| ARPO Stock Forecast | Aerpio Pharmaceuticals | - |
6
|
$30.30 | Buy/Sell | $0.00 | -100.00% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$27.50 | Buy/Sell | $49.11 | 81.82% |
.jpg)